EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparative Prognostic Roles of β-Catenin Expression and Tumor–Stroma Ratio in Pancreatic Cancer: Neoadjuvant Chemotherapy vs. Upfront Surgery

Shu Oikawa iD, Hiroyuki Mitomi iD, So Murai iD, Akihiro Nakayama, Seiya Chiba iD, Shigetoshi Nishihara iD, Yu Ishii iD, Toshiko Yamochi iD, Hitoshi Yoshida

Current Oncology · 2025

DOI: 10.3390/curroncol32100578 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Current Oncology, 2025. Verfasst von Shu Oikawa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Gastroenterology, Showa Medical University School of Medicine, Tokyo 142-8555, Japan. Hauptthemen laut MEDLINE: beta Catenin, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The benefit of neoadjuvant chemotherapy (NAC) over upfront surgery (UFS) for resectable pancreatic ductal adenocarcinoma (PDAC) is increasingly recognized, yet prognostic biomarkers remain undefined. We evaluated tumor–stroma ratio (TSR), β-catenin (β-CTN) expression, and tumor budding (TB) in 84 resected PDACs (35 NAC, 49 UFS) using digital image analysis of multi-cytokeratin (m-CK) and β-CTN immunohistochemistry. TSR was defined as the proportion of malignant epithelial area within the tumor, and the β-CTN/m-CK index as the ratio of β-CTN to m-CK immunoreactivity in tumor tissue relative to intralobular ducts. TB was significantly less frequent in NAC than UFS (p = 0.003), suggesting that NAC may indirectly modulate epithelial–mesenchymal transition, with TB regarded as its morphological correlate. In the NAC cohort, low TSR was associated with more favorable histological response (Evans IIa/IIb, median 7%; Evans I, 16%; p = 0.009), likely reflecting NAC-induced tumor shrinkage with relative stromal predominance. In multivariable analysis, low β-CTN/m-CK index (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta CateninPancreatic NeoplasmsCarcinoma, Pancreatic DuctalHumansNeoadjuvant TherapyFemalePrognosisMaleMiddle AgedAgedBiomarkers, TumorAdult

Stichwörter der Autor:innen

digital image analysisimmunohistochemistryneoadjuvant chemotherapypancreatic ductal adenocarcinomatumor buddingtumor–stroma ratioupfront surgerywhole-slide imagingβ-catenin

Substanzen

beta CateninCTNNB1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medicine, Division of Gastroenterology, Showa Medical University School of Medicine, Tokyo 142-8555, Japan.
  • Department of Diagnostic Pathology, Showa Medical University School of Medicine, Tokyo 142-8555, Japan.
  • Department of Gastroenterological Surgery, Showa Medical University School of Medicine, Koto Toyosu Hospital, Tokyo 135-8577, Japan.

ORCID-Profile: Shu Oikawa, Hiroyuki Mitomi, So Murai, Seiya Chiba, Shigetoshi Nishihara, Yu Ishii, Toshiko Yamochi

Zitieren

APA

Oikawa, S., Mitomi, H., Murai, S., Nakayama, A., Chiba, S., Nishihara, S., Ishii, Y., Yamochi, T., & Yoshida, H. (2025). Comparative Prognostic Roles of β-Catenin Expression and Tumor–Stroma Ratio in Pancreatic Cancer: Neoadjuvant Chemotherapy vs. Upfront Surgery. Current Oncology. https://doi.org/10.3390/curroncol32100578

Vancouver

Oikawa S, Mitomi H, Murai S, Nakayama A, Chiba S, Nishihara S, et al. Comparative Prognostic Roles of β-Catenin Expression and Tumor–Stroma Ratio in Pancreatic Cancer: Neoadjuvant Chemotherapy vs. Upfront Surgery. Current Oncology. 2025. doi:10.3390/curroncol32100578

BibTeX
@article{Oikawa2025,
  author = {Oikawa, Shu and Mitomi, Hiroyuki and Murai, So and Nakayama, Akihiro and Chiba, Seiya and Nishihara, Shigetoshi and Ishii, Yu and Yamochi, Toshiko and Yoshida, Hitoshi},
  title = {Comparative Prognostic Roles of β-Catenin Expression and Tumor–Stroma Ratio in Pancreatic Cancer: Neoadjuvant Chemotherapy vs. Upfront Surgery},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32100578}
}
Kostenlos starten →